Teva Pharmaceutical Industries Limited Stock NYSE
Stocks
TEVA
US8816242098
Pharmaceuticals
OTC Markets Traded| Market Cap | 48.14B 42.88B 39.75B 36B 67.7B 4,562B 68.65B 476B 187B 2,387B 181B 177B 7,619B | P/E 2026 * |
54.7x | P/E 2027 * | 22x |
|---|---|---|---|---|---|
| Enterprise Value | 59.47B 52.97B 49.11B 44.48B 83.64B 5,636B 84.82B 588B 231B 2,949B 223B 218B 9,413B | EV / Sales 2026 * |
3.57x | EV / Sales 2027 * | 3.29x |
| Free-Float |
91.17% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Teva Pharmaceutical Industries Limited
| 1 day | +2.04% |
| Manager | Title | Age | Since |
|---|---|---|---|
Richard Francis
CEO | Chief Executive Officer | 57 | 2022-12-31 |
Eli Kalif
DFI | Director of Finance/CFO | 53 | 2019-12-21 |
Matthew Shields
COO | Chief Operating Officer | 52 | 2024-06-02 |
| Director | Title | Age | Since |
|---|---|---|---|
Amir Elstein
BRD | Director/Board Member | 69 | 2008-12-31 |
Sol Barer
CHM | Chairman | 78 | 2017-02-05 |
Rosemary Crane
BRD | Director/Board Member | 65 | 2015-08-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 8/5/26 | Sell | Director | -17 | 0.0000% | ||
| 8/3/26 | Exercice | Chief Technology Officer | 131,066 | 0.0112% | ||
| 8/3/26 | Exercice | Head of Human Resources | 38,481 | 0.0033% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 16.66B 14.83B 13.75B 12.46B 23.42B 1,578B 23.75B 165B 64.67B 826B 62.47B 61.17B 2,636B | 17.23B 15.34B 14.22B 12.88B 24.22B 1,632B 24.57B 170B 66.88B 854B 64.61B 63.27B 2,726B |
| Net income | 1.07B 951M 881M 798M 1.5B 101B 1.52B 10.54B 4.14B 52.92B 4B 3.92B 169B | 2.41B 2.14B 1.99B 1.8B 3.38B 228B 3.43B 23.76B 9.34B 119B 9.02B 8.83B 381B |
| Net Debt | 11.34B 10.1B 9.36B 8.48B 15.94B 1,074B 16.17B 112B 44.01B 562B 42.52B 41.63B 1,794B | 8.53B 7.59B 7.04B 6.38B 11.99B 808B 12.16B 84.24B 33.11B 423B 31.98B 31.32B 1,349B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
